Chemoinformaics analysis of 3,9-Dihydroxypterocarpan
| Molecular Weight | 256.257 | nRot | 0 |
| Heavy Atom Molecular Weight | 244.161 | nRig | 20 |
| Exact Molecular Weight | 256.074 | nRing | 4 |
| Solubility: LogS | -3.739 | nHRing | 2 |
| Solubility: LogP | 2.618 | No. of Aliphatic Rings | 2 |
| Acid Count | 0 | No. of Aromatic Rings | 2 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 0 |
| Atoms Count | 31 | No. of Aliphatic Hetero Cycles | 2 |
| No. of Heavy Atom | 19 | No. of Aromatic Carbocycles | 2 |
| nHetero | 4 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 12 | No. of Saturated Hetero Cycles | 0 |
| No. of Carbon atom | 15 | No. of Saturated Rings | 0 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 12 |
| No. of Oxygen atom | 4 | No. of Arom Bond | 12 |
| nHA | 4 | APOL | 36.2595 |
| nHD | 2 | BPOL | 15.5105 |
| QED | 0.761 |
| Synth | 3.279 |
| Natural Product Likeliness | 2.007 |
| NR-PPAR-gamma | 0.018 |
| Lipinski | Accepted |
| Pfizer | Accepted |
| GSK | Accepted |
| Golden Triangle | Accepted |
| Pgp-inh | 0.004 |
| Pgp-sub | 0.018 |
| HIA | 0.006 |
| CACO-2 | -4.793 |
| MDCK | 0.00000886 |
| BBB | 0.049 |
| PPB | 0.968381 |
| VDSS | 0.741 |
| FU | 0.0350912 |
| CYP1A2-inh | 0.928 |
| CYP1A2-sub | 0.822 |
| CYP2c19-inh | 0.81 |
| CYP2c19-sub | 0.233 |
| CYP2c9-inh | 0.784 |
| CYP2c9-sub | 0.948 |
| CYP2d6-inh | 0.852 |
| CYP2d6-sub | 0.894 |
| CYP3a4-inh | 0.714 |
| CYP3a4-sub | 0.333 |
| CL | 12.39 |
| T12 | 0.598 |
| hERG | 0.081 |
| Ames | 0.898 |
| ROA | 0.159 |
| SkinSen | 0.914 |
| Carcinogencity | 0.613 |
| EI | 0.902 |
| Respiratory | 0.407 |
| NR-Aromatase | 0.379 |
| Antiviral | No |
| Prediction | 0.680182 |